This transcript has been edited for clarity.
Hello. I am Dr JoAnn Manson, professor of medicine at Harvard Medical School and Brigham and Women's Hospital in Boston, Massachusetts. I'd like to talk with you about a recent updated meta-analysis of randomized trials of omega-3 fatty acids and cardiovascular disease (CVD). I was a coauthor of this meta-analysis.
Our goals were twofold:
To update a meta-analysis including the recent large-scale randomized trials of omega-3s, such as ASCEND, VITAL, and REDUCE-IT; and
To do the meta-analysis with and without the inclusion of data from the REDUCE-IT trial, which was an outlier. This trial used a very high dose (4 g/day) of purified eicosapentaenoic acid (EPA) and found a very large magnitude of risk reduction.
We also wanted to do, for the first time, a dose-response analysis of omega-3s and CVD to see whether there was a dose-response gradient, and to, again, conduct this analysis both with and without REDUCE-IT.
We included 13 randomized trials with more than 127,000 participants in this report. Even in the analyses excluding REDUCE-IT, we saw a significant reduction in myocardial infarction and coronary heart diseasedeath, CVD death, and total CVD events, but no significant reduction in
COMMENTARY
Omega-3s and CVD Prevention: A Promising Future?
JoAnn E. Manson, MD, DrPH
DisclosuresNovember 06, 2019
This transcript has been edited for clarity.
Hello. I am Dr JoAnn Manson, professor of medicine at Harvard Medical School and Brigham and Women's Hospital in Boston, Massachusetts. I'd like to talk with you about a recent updated meta-analysis of randomized trials of omega-3 fatty acids and cardiovascular disease (CVD). I was a coauthor of this meta-analysis.
Our goals were twofold:
To update a meta-analysis including the recent large-scale randomized trials of omega-3s, such as ASCEND, VITAL, and REDUCE-IT; and
To do the meta-analysis with and without the inclusion of data from the REDUCE-IT trial, which was an outlier. This trial used a very high dose (4 g/day) of purified eicosapentaenoic acid (EPA) and found a very large magnitude of risk reduction.
We also wanted to do, for the first time, a dose-response analysis of omega-3s and CVD to see whether there was a dose-response gradient, and to, again, conduct this analysis both with and without REDUCE-IT.
We included 13 randomized trials with more than 127,000 participants in this report. Even in the analyses excluding REDUCE-IT, we saw a significant reduction in myocardial infarction and coronary heart diseasedeath, CVD death, and total CVD events, but no significant reduction in
Medscape Ob/Gyn © 2019 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: JoAnn E. Manson. Omega-3s and CVD Prevention: A Promising Future? - Medscape - Nov 06, 2019.
Tables
Authors and Disclosures
Authors and Disclosures
Author(s)
JoAnn E. Manson, MD, DrPH
Professor of Medicine and the Michael and Lee Bell Professor of Women's Health, Harvard Medical School; Chief, Division of Preventive Medicine, Brigham and Women's Hospital, Boston, Massachusetts; Past President, North American Menopause Society, 2011-2012
Disclosure: JoAnn E. Manson, MD, DrPH, has disclosed the following relevant financial relationships:
Received study pill donation and infrastructure support from: Mars Symbioscience (for the COSMOS trial)